Published in Int J Oncol on July 01, 2006
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun (2015) 1.03
TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS One (2013) 1.00
Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol (2010) 0.97
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS One (2010) 0.94
Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer (2013) 0.93
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer (2012) 0.92
Integrative analysis of a cancer somatic mutome. Mol Cancer (2007) 0.92
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One (2012) 0.92
The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets (2008) 0.87
Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int (2014) 0.87
An integrative approach to identifying cancer chemoresistance-associated pathways. BMC Med Genomics (2011) 0.85
Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics. J Biomed Opt (2012) 0.84
The Role of Long Non-Coding RNAs in Ovarian Cancer. Iran Biomed J (2016) 0.84
MicroRNA-500 sustains nuclear factor-κB activation and induces gastric cancer cell proliferation and resistance to apoptosis. Oncotarget (2015) 0.83
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer (2015) 0.78
Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. PLoS One (2014) 0.77
Interaction of TACC proteins with the FHL family: implications for ERK signaling. J Cell Commun Signal (2007) 0.76
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res (2014) 0.76
A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells. Oncotarget (2016) 0.76
Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1. Mol Cancer (2014) 0.75
Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro. Mol Med Rep (2017) 0.75
Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections. PLoS One (2015) 0.75
AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway. Oncol Lett (2017) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature (2004) 3.65
Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol (2005) 2.79
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem (2002) 2.16
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst (2005) 2.04
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Quantum plasmon resonances controlled by molecular tunnel junctions. Science (2014) 1.89
Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem (2003) 1.88
Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A (2012) 1.82
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol (2004) 1.77
Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol (2009) 1.70
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat (2011) 1.68
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol (2009) 1.59
Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol (2012) 1.57
Preoperative bowel preparation in gynecologic oncology: a review of practice patterns and an impetus to change. Int J Gynecol Cancer (2011) 1.39
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol (2013) 1.36
Extraction and amplification of DNA from formalin-fixed, paraffin-embedded tissues. Appl Immunohistochem Mol Morphol (2002) 1.34
TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer (2011) 1.30
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
YY1 is regulated by O-linked N-acetylglucosaminylation (O-glcNAcylation). J Biol Chem (2003) 1.25
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther (2012) 1.23
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer (2008) 1.18
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer (2014) 1.18
The structure of the harmonin/sans complex reveals an unexpected interaction mode of the two Usher syndrome proteins. Proc Natl Acad Sci U S A (2010) 1.18
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer (2011) 1.17
Assembling stable hair cell tip link complex via multidentate interactions between harmonin and cadherin 23. Proc Natl Acad Sci U S A (2009) 1.16
Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res (2003) 1.16
Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res (2010) 1.15
Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J Biol Chem (2011) 1.14
Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol (2007) 1.14
Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer (2006) 1.14
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
Impacts of Shewanella oneidensis c-type cytochromes on aerobic and anaerobic respiration. Microb Biotechnol (2010) 1.13
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol (2012) 1.11
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res (2010) 1.07
The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology (2005) 1.05
Laparoscopic sentinel node mapping in early-stage cervical cancer. Gynecol Oncol (2003) 1.05
PEDF regulates vascular permeability by a γ-secretase-mediated pathway. PLoS One (2011) 1.05
No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev (2005) 1.04
Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer (2010) 1.03
Sequencing and comparative analysis of the straw mushroom (Volvariella volvacea) genome. PLoS One (2013) 1.03
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Expression analysis of the NDRG2 gene in mouse embryonic and adult tissues. Cell Tissue Res (2006) 1.03
Web tutorials: bibliographic instruction in a new medium. Med Ref Serv Q (2006) 1.02
p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer (2002) 1.02
Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis (2013) 1.01
The fixed-size Luria-Delbruck model with a nonzero death rate. Math Biosci (2007) 1.01
Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (2012) 1.01
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Invest Ophthalmol Vis Sci (2011) 1.00
RCAS1 is associated with ductal breast cancer progression. Biochem Biophys Res Commun (2002) 0.99
Identification and validation of rice reference proteins for western blotting. J Exp Bot (2011) 0.99
Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol (2006) 0.99
Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther (2011) 0.98
Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol (2008) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
High capacity Na-storage and superior cyclability of nanocomposite Sb/C anode for Na-ion batteries. Chem Commun (Camb) (2012) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem (2012) 0.97
MicroRNA-21 expression is associated with overall survival in patients with glioma. Diagn Pathol (2013) 0.97
Influence of Dll4 via HIF-1α-VEGF signaling on the angiogenesis of choroidal neovascularization under hypoxic conditions. PLoS One (2011) 0.97
Pellicle formation in Shewanella oneidensis. BMC Microbiol (2010) 0.97
Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics (2012) 0.96
Matrine, a novel autophagy inhibitor, blocks trafficking and the proteolytic activation of lysosomal proteases. Carcinogenesis (2012) 0.96
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica (2013) 0.96
NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats. PLoS One (2011) 0.95
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (2010) 0.95
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood (2013) 0.95